Results 11 to 20 of about 148,376 (307)

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria

Haematologica, 2020
Patients with systemic immunoglobulin light chain amyloidosis (AL) with no evidence of cardiac involvement by consensus criteria have excellent survival, but 20% will die within 5 years of diagnosis and prognostic factors remain poorly characterised.
Faye A. Sharpley, Marianna Fontana, Ana Martinez-Naharro, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Carol J. Whelan, Philip N. Hawkins, Ashutosh D. Wechalekar   +10 more
doaj   +1 more source

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Biomarker Research, 2023
Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances ...
Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart   +8 more
doaj   +1 more source

Amyloidosis [PDF]

Postgraduate Medical Journal, 2001
Abstract Amyloidosis is not a single disease but a series of diseases in which there is extracellular deposition of a protein which, although it may be derived from different and unrelated sources, folds into a β pleated sheet. There have recently been significant advances in elucidating the pathogenesis and in the ...
M F, Khan, R H, Falk
openaire   +2 more sources

Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

European Journal of Heart Failure, 2021
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions ...
P. García-Pavía, C. Rapezzi, Y. Adler, M. Arad, C. Basso, A. Brucato, I. Burazor, A. Caforio, T. Damy, U. Eriksson, M. Fontana, J. Gillmore, E. Gonzalez-Lopez, M. Grogan, S. Heymans, M. Imazio, I. Kindermann, A. Kristen, M. Maurer, G. Merlini, A. Pantazis, S. Pankuweit, A. Rigopoulos, A. Linhart   +23 more
semanticscholar   +1 more source

Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution

Blood Cancer Journal, 2022
From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal –PPs- 17.6%, extramedullary –EMPs-1.9%).
Raquel Jiménez-Segura, Laura Rosiñol, Ma Teresa Cibeira, Carlos Fernández de Larrea, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, Esther Bladé, David F. Moreno, Aina Oliver-Caldés, Joan Bladé   +9 more
doaj   +1 more source

Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not

Biomedicines, 2022
Cardiac amyloidosis (CA), caused by the deposition of insoluble amyloid fibrils, impairs different cardiac structures, altering not only left ventricle (LV) systo-diastolic function but also atrial function and the conduction system.
Alessia Argirò, Annamaria Del Franco, Carlotta Mazzoni, Marco Allinovi, Alessia Tomberli, Roberto Tarquini, Carlo Di Mario, Federico Perfetto, Francesco Cappelli, Mattia Zampieri   +9 more
doaj   +1 more source

Amyloidosis in Alzheimer’s Disease: Pathogeny, Etiology, and Related Therapeutic Directions

Molecules, 2022
The amyloid hypothesis of Alzheimer’s disease has long been the predominant theory, suggesting that Alzheimer’s disease is caused by the accumulation of amyloid beta protein (Aβ) in the brain, leading to neuronal toxicity in the central nervous system ...
Chen Ma, Fenfang Hong, Shulong Yang
semanticscholar   +1 more source

Cardiac amyloidosis and aortic stenosis: a state-of-the-art review

European Heart Journal Open, 2023
Cardiac amyloidosis is caused by the extracellular deposition of amyloid fibrils in the heart, involving not only the myocardium but also any cardiovascular structure.
Vikash Jaiswal, Vibhor Agrawal, Yashita Khulbe, Muhammad Hanif, H. Huang, Maha Hameed, A. Shrestha, F. Perone, Charmy Parikh, Sabas Gomez, K. Paudel, Jerome S. Zacks, Kendra J. Grubb, Salvatore De Rosa, Alessia Gimelli   +14 more
semanticscholar   +1 more source

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage

ESC Heart Failure, 2020
Aims Cardiac transthyretin amyloidosis (ATTR‐CM) is a progressive and fatal condition. Prognosis can be determined at diagnosis according to the National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage.
Steven Law, Aviva Petrie, Liza Chacko, Oliver C. Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez‐Naharro, Helen J. Lachmann, Carol J. Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore   +14 more
doaj   +1 more source

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Global Heart, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal condition that requires early diagnosis, management, and specific treatment.
D. Brito, Fabiano Castro Albrecht, Diego Perez de Arenaza, Nicole Bart, Nathan Better, I. Carvajal-Juárez, I. Conceição, Thibaud Damy, S. Dorbala, Jean-Christophe Fidalgo, P. García-Pavía, Junbo Ge, J. Gillmore, Jacek Grzybowski, L. Obici, Daniel Piñero, Claudio Rapezzi, Mitsuharu Ueda, Fausto J. Pinto   +18 more
semanticscholar   +1 more source